成纤维细胞生长因子受体1/Klothoβ激动剂BFKB8488A改善糖尿病或NAFLD患者的血脂和肝脏健康标志物:一项1b期随机试验
BFKB8488A是靶向成纤维细胞生长因子受体1c和Klothoβ的双特异性抗体。这项1b期研究评估了BFKB8488A在2型糖尿病(T2DM)或NAFLD患者中的安全性、耐受性、药代动力学、免疫原性和药效学。153例患者(T2DM:91例;NAFLD:62例)随机接受不同剂量水平和给药间隔(每周、每2周或每4周)的BFKB8488A或安慰剂治疗12周。BFKB8488A耐受性良好,导致甘油三酯降低、HDL改善,两个人群的肝脏健康标志物均有改善趋势,NAFLD患者的肝脏脂肪显著减少。
要点
- BFKB8488A在T2DM或NAFLD患者中耐受性良好,不良事件发生率BFKB8488A组68.6% vs 安慰剂组59.4%。
- BFKB8488A呈现非线性药代动力学,暴露量增加大于剂量比例。
- NAFLD患者中,高暴露三分位组肝脏脂肪平均较基线减少49.0%,安慰剂组减少0.1%。
核心结论
- BFKB8488A在T2DM或NAFLD患者中耐受性良好,导致甘油三酯降低、HDL改善,两个人群的肝脏健康标志物均有改善趋势,NAFLD患者的肝脏脂肪显著减少。
研究设计与样本
- 1b期随机试验,纳入153例患者(T2DM:91例;NAFLD:62例),随机接受不同剂量水平和给药间隔(每周、每2周或每4周)的BFKB8488A或安慰剂治疗12周。
- 主要结局为BFKB8488A的安全性。
主要发现
- 102例患者(62.7%)报告至少一次不良事件(BFKB8488A组83例[68.6%];安慰剂组19例[59.4%])。
- BFKB8488A呈现非线性药代动力学,暴露量增加大于剂量比例。
- 治疗中出现抗药抗体发生率为22.7%。
- 观察到HDL暴露依赖性升高和甘油三酯降低的趋势。
- 第85天,丙氨酸氨基转移酶和天冬氨酸氨基转移酶在中暴露三分位组分别降低0.7%和9.2%,高暴露三分位组分别降低7.3%和11.2%,而安慰剂组分别升高7.5%和17%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: BFKB8488A is a bispecific antibody targeting fibroblast growth factor receptor 1c and Klothoβ. This phase 1b study assessed safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics of BFKB8488A in patients with type 2 diabetes mellitus (T2DM) or NAFLD. APPROACH AND RESULTS: Patients were randomized to receive multiple doses of BFKB8488A at various dose levels and dosing intervals (weekly, every 2 weeks, or every 4 weeks) or placebo for 12 weeks. The primary outcome was the safety of BFKB8488A. Overall, 153 patients (T2DM: 91; NAFLD: 62) were enrolled and received at least one dose of treatment. Of these, 102 patients (62.7%) reported at least one adverse event (BFKB8488A: 83 [68.6%]; placebo: 19 [59.4%]). BFKB8488A exhibited nonlinear pharmacokinetics, with greater than dose-proportional increases in exposure. The treatment-emergent antidrug antibody incidence was 22.7%. Overall, trends in exposure-dependent increases in high-density lipoprotein (HDL) and decreases in triglyceride levels were observed. Decreases in alanine aminotransferase and aspartate aminotransferase were 0.7% and 9.2% for medium exposure and 7.3% and 11.2% for high-exposure tertiles, compared with increases of 7.5% and 17% in the placebo group, respectively, at Day 85. In patients with NAFLD, the mean decrease from baseline liver fat was 13.0%, 34.5%, and 49.0% in the low-, medium-, and high-exposure tertiles, respectively, compared with 0.1% with placebo at Day 85. CONCLUSIONS: BFKB8488A was adequately tolerated in patients with T2DM or NAFLD, leading to triglyceride reduction, HDL improvements, and trends in improvement in markers of liver health for both populations and marked liver fat reduction in patients with NAFLD. ( ClinicalTrials.gov : NCT03060538).
引用
- Wong C, Dash A, Fredrickson J, et al. Fibroblast growth factor receptor 1/Klothoβ agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial. Hepatology. 2022. PMID: 35993161. doi:10.1002/hep.32742
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。